NIH Awards United Therapeutics $45 Million Contract To Develop Potential Oral Treatment For Viruses

The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years “to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue,” the Associated Press/Washington Post reports (10/10). The funding comes from NIH’s National Institute of Allergy and Infectious Diseases and will be used “for studies directed at the development of a broad-spectrum antiviral drug based on [United Therapeutics’] glycobiology antiviral platform,” according to a press release from United Therapeutics, which adds, “Funding will support the development of a candidate compound through preclinical safety and efficacy studies toward potential clinical trials against dengue” (10/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.